The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.
 
Kevin J. Harrington
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Merck
Speakers' Bureau - Amgen; Merck
 
Martin David Forster
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Lilly; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Merck; MSD; Pfizer; Roche
 
Magnus Dillon
Research Funding - AstraZeneca
 
Lorna Grove
Consulting or Advisory Role - Amgen
 
Sola Adeleke
No Relationships to Disclose
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jane S. Diamond
No Relationships to Disclose
 
Henrik Hannus
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kandance Cooper
Employment - Daiichi Sankyo
 
Jonathan Greenberg
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo